WHO says vaccine safety top priority, as AstraZeneca pauses study

FILE PHOTO: A logo is pictured on the headquarters of the World Health Orgnaization (WHO) ahead of a meeting of the Emergency Committee on the novel coronavirus (2019-nCoV) in Geneva, Switzerland, January 30, 2020. REUTERS/Denis Balibouse/File Photo

ZURICH—Safety of a prospective vaccine for COVID-19 comes “first and foremost,” the World Health Organization’s chief scientist said on Wednesday, as a trial of a candidate from AstraZeneca was paused, at least temporarily, due to concerns over side effects.

“Just because we talk about speed…it doesn’t mean we start compromising or cutting corners on what would normally be assessed,” Dr. Soumya Swaminathan said on a social media event. “The process still has to follow through rules of the game. For drugs and vaccines which are given to people, you have to test their safety, first and foremost.”

WHO officials did not immediately respond directly to questions from Reuters over the move by AstraZeneca to pause global trials, including large late-stage trials, of its experimental coronavirus vaccine due to an unexplained illness in a study participant.

For more news about the novel coronavirus click here.
What you need to know about Coronavirus.
For more information on COVID-19, call the DOH Hotline: (02) 86517800 local 1149/1150.

The Inquirer Foundation supports our healthcare frontliners and is still accepting cash donations to be deposited at Banco de Oro (BDO) current account #007960018860 or donate through PayMaya using this link.